Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-09-17
2011-12-27
Lundgren, Jeffrey S (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S327000
Reexamination Certificate
active
08084465
ABSTRACT:
The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis.
REFERENCES:
patent: 3839346 (1974-10-01), Gadekar
patent: 4866078 (1989-09-01), Perrior et al.
patent: 5039807 (1991-08-01), Perrior et al.
patent: 5310562 (1994-05-01), Margolin
patent: 5716632 (1998-02-01), Margolin
patent: 5789426 (1998-08-01), Hanauske-Abel
patent: 5939439 (1999-08-01), Anthony et al.
patent: 5962478 (1999-10-01), Margolin
patent: 6048823 (2000-04-01), Yamaguchi et al.
patent: 6090822 (2000-07-01), Margolin
patent: 6265349 (2001-07-01), Yamaguchi et al.
patent: 6294350 (2001-09-01), Peterson
patent: 6300349 (2001-10-01), Margolin
patent: 6492395 (2002-12-01), Scheiwe et al.
patent: 6956044 (2005-10-01), Margolin
patent: 7067540 (2006-06-01), Devadas et al.
patent: 2003/0216257 (2003-11-01), Sagasser et al.
patent: 2004/0058964 (2004-03-01), Devadas et al.
patent: 2006/0039931 (2006-02-01), Scheiwe
patent: 2006/0100249 (2006-05-01), Smith
patent: 2006/0110358 (2006-05-01), Hsu
patent: 2006/0167064 (2006-07-01), Seth
patent: 2006/0211694 (2006-09-01), Devadas et al.
patent: 2006/0276510 (2006-12-01), Abu-Shakra et al.
patent: 2006/0279709 (2006-12-01), Yamamoto
patent: 1386737 (2002-12-01), None
patent: 0 458 861 (1996-03-01), None
patent: 1138329 (2001-10-01), None
patent: 0 383 591 (2001-11-01), None
patent: 0 702 551 (2002-09-01), None
patent: 1 069 898 (2004-05-01), None
patent: 1 261 338 (2006-06-01), None
patent: WO 97/41830 (1997-11-01), None
patent: WO-00-44381 (2000-08-01), None
patent: WO 01/58448 (2001-08-01), None
patent: WO 2005/047256 (2005-05-01), None
patent: WO 2006/004100 (2006-01-01), None
patent: WO 2006/108354 (2006-10-01), None
patent: WO 2006/109876 (2006-10-01), None
Pu et al., “Protective effects of 2-ethyl-3-hydroxy-6-phenylthio-4-(1H)-pyridinone on injured primary cultured rat hepatocytes induced by CC14” 2002, Chin Pharm J. vol. 37(4): 267-271 (In Chinese with English abstract).
Chin, “Protective effects of 2-ethyl-3-hydroxy-6-phenylthio-4(1H)-pyridinone on injured primary cultured rat hepatocytes induced by CCI4,” Pharm J. 37(4):267-271 (2002).
Ansel, Pharmaceutical dosage forms and drug delivery systems, 7thed., pp. 87-92, 1999.
Patani and LaVoie, “Bioisoterism: A Rational Approach in Drug Design,” Chem Rev 96(8):3147-3176 (1996).
Worbel et al., “Orally active aldose reductase inhibitors derived from bioisosterie substitutions on tolrestat,” J Med Chem 32(11):2493-3000 (1989) (Abstract).
Lundgren Jeffrey S
Rao Savitha
Shanghai Genomics, Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Derivatives of pryidone and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of pryidone and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of pryidone and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311301